Investor Presentation Q1 2023
96
Investor presentation
First three months of 2023
Novo NordiskⓇ
Entering phase 3 development of semaglutide in Alzheimer's
disease was based on a number of data points
Å
Real world evidence trials
Four RWE studies show reduced risk of
dementia or AD with GLP-1
Danish registry¹
11% lower risk of dementia per year of
GLP-1 exposure
TRUVEN claims database¹
31% lower risk of dementia after >2 years of
GLP-1 exposure
Danish registry²
•
42% lower odds of dementia after
GLP-1 exposure
FAERS (FDA database)³
64% lower odds of Alzheimer's disease after
liraglutide exposure
AD: Alzheimer's disease; CI: confidence interval; RWE: Real world evidence
Randomised controlled trials
53% lower risk of dementia diagnosis with
liraglutide/semaglutide in NN's CVOTs in T2D4
Less decline in cerebral glucose metabolism
(FDG-PET) with liraglutide in AD5
Reduced incidence of major adverse CV
events in T2D with semaglutide incl. stroke
Systemic anti-inflammatory effects with
semaglutide7,8
Short-term memory improvement with
liraglutide in people with obesity⁹
Reduced cognitive decline with dulaglutide in
patients with T2D10
Pre-clinical studies
Improved memory function with GLP-111
incl. semaglutide12
Reduced phospho-tau accumulation 13
Reduced neuroinflammation with GLP-114,15
incl. semaglutide16
Reduced atherosclerosis with liraglutide and
semaglutide17
Systemic anti-inflammatory effects with
semaglutide17
¹NN data on file, Danish register: Dementia cases based on diagnosis (ICD10) or treatment (anticholinesterases, memantine) codes; TRUVEN: Dementia cases based on SNOMED ids for all diagnoses (ICD-10) or treatment (anticholinesterases, memantine);
2Wium-Andersen IK et al. Eur J Endocrinol. 2019;181(5):499-507; 3Akimoto H et al. Am J Alzheimers Dis Other Demen. 2020;35:1-11; 4Ballard et al. Presented online at the Alzheimer's Association International Conference (AAIC), 27-31 July 2020; 5Gejl M et al. Front
Aging Neurosci 2016;8:108; 6Husain M et al. Diabetes Obes Metab 2020;22:442-451; 7Aroda VR et al. Diabetes Care 2019;42:1724-1732; 8Rodbard HW et al. Diabetes Care 2019;42:2272-2281; 9Vadini F et al. Int J Obes (Lond) 2020;44:1254-1263; 10Cukierman-Yaffe
T et al. Lancet Neurol 2020;19:582-590 11Hansen HH et al. J Alzheimers Dis 2015;46:877-888; 12Preliminary data in NN ongoing pre-clinical studies; 13Hansen HH et al. Brain Res 2016;1634:158-170; 14Brundin L et al. Nature Med 2018;24:900-902; 15Yun SP et al.
Nature Med 2018;24:931-938; 16Secher A et al. Oral presentation at Virtual Alzheimer's Disease/Parkinson's Disease International Conference, 9-14 March 2021; 17Rakipovski G et al. JACC Basic Transl Sci 2018;3:844-857View entire presentation